Bourgeon Capital Management LLC Buys New Stake in Illumina, Inc. (NASDAQ:ILMN)

Bourgeon Capital Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 80,428 shares of the life sciences company's stock, valued at approximately $6,381,000. Bourgeon Capital Management LLC owned 0.05% of Illumina as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Golden State Wealth Management LLC bought a new position in shares of Illumina in the 4th quarter worth approximately $32,000. Fourth Dimension Wealth LLC bought a new position in shares of Illumina in the 4th quarter worth approximately $40,000. Assetmark Inc. lifted its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina in the 4th quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina in the 4th quarter worth approximately $48,000. Institutional investors own 89.42% of the company's stock.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is currently owned by insiders.

Illumina Price Performance

Shares of Illumina stock traded up $0.41 on Friday, hitting $82.66. 1,614,255 shares of the company traded hands, compared to its average volume of 2,291,075. The stock has a market capitalization of $13.09 billion, a P/E ratio of -10.76, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The business has a 50-day simple moving average of $77.90 and a 200 day simple moving average of $104.72.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.98 earnings per share. Research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ILMN. Guggenheim lowered their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Morgan Stanley decreased their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Finally, Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus target price of $128.84.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.